Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2012. The report details a specific share repurchase transaction executed on November 9, 2012, under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 625,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,373.5 pence per share; lowest price paid was 1,354.5 pence per share.
- Treasury Holdings (Settled): 525,440,427 shares (9.65% of total issued share capital).
- Treasury Holdings (Including Unsettled): 528,265,427 shares (10.74% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,920,020,785 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 625,000 shares on November 9, 2012. Consequently, the percentage of shares held in Treasury increased to 10.74% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (525,440,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,920,020,785 shares in issue) for disclosure threshold assessments.
- Review the remaining authority under the May 3, 2012 shareholder mandate for future buybacks.